Spegra Tablet (Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg)

What is Spegra Tablet (Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg)?

Spegra Tablet is a fixed-dose combination antiretroviral medication used for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults and certain pediatric patients. It contains three active ingredients: Dolutegravir 50mg, an integrase inhibitor; Emtricitabine 200mg, a nucleoside analog reverse transcriptase inhibitor; and Tenofovir Alafenamide 25mg, a newer prodrug of tenofovir with improved delivery to target cells. Together, these components work synergistically to inhibit key stages of the HIV replication cycle, significantly reducing viral load and helping preserve immune function.

Key features

• Triple-action formula — Combines three antiretrovirals in one tablet for simplified HIV treatment.
• Once-daily dosing — Designed for daily use, improving medication adherence.
• Tenofovir Alafenamide — Offers potent antiviral activity with reduced risk to kidneys and bones.
• Dolutegravir-based — High genetic barrier to resistance, effective in treatment-naive and some experienced patients.
• Prescription required — Not available over-the-counter; must be used under medical supervision.
• WHO-recommended regimen — Aligns with global HIV treatment guidelines for first-line therapy.
• Manufactured to quality standards — Sourced from licensed pharmaceutical suppliers.

Who is Spegra Tablet (Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg) for?

This medication is intended for adults and pediatric patients (weighing at least 25 kg) with HIV-1 infection, including those starting antiretroviral therapy for the first time. It is not a cure for HIV but helps control the virus over time. It is especially suitable for individuals seeking a once-daily, single-tablet regimen with a favorable safety profile. Patients with known hypersensitivity to any component should avoid use. Consultation with a healthcare provider is essential before starting treatment.

How does Spegra Tablet (Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg) compare?

Compared to older HIV regimens requiring multiple pills or less tolerable formulations like Tenofovir Disoproxil Fumarate (TDF), Spegra offers a modern, single-tablet solution with improved safety. Its use of Tenofovir Alafenamide reduces the risk of renal and bone side effects. Versus other integrase-based regimens, it provides a high barrier to resistance. While similar to branded equivalents, it offers a cost-effective alternative without sacrificing efficacy, assuming bioequivalence and quality sourcing.